Tumor angiogenesis: past, present and the near future
摘要:
The concept of treating by inhibiting was first articulated almost 30 years ago. For the next 10 years it attracted little scientific interest. This situation changed, relatively slowly, over the succeeding decade with the discovery of the first pro-angiogenic molecules such as and vascular endothelial growth factor (), and the of methods of successfully growing vascular endothelial cells in culture as well as in vivo assays of . However, the 1990s have witnessed a striking change in both attitude and interest in and anti-angiogenic drug , to the point where a remarkably diverse group of over 24 such drugs is currently undergoing evaluation in phase I, II or III clinical trials. In this review I will discuss the many reasons for this. These features, together with other recent discoveries have created intense interest in initiating and expanding anti-angiogenic drug discovery programs in both academia and industry, and the testing of such newly developed drugs, either alone, or in various combinations with conventional cytotoxic therapeutics. However, significant problems remain in the clinical application of inhibitors such as the need for surrogate markers to monitor the effects of such drugs when they do not cause regressions, and the design of clinical trials. Also of concern is that the expected need to use anti-angiogenic drugs chronically will lead to delayed toxic side effects in , which do not appear in , especially in short-term studies.
展开
关键词:
α-SMA, α-smooth muscle action bFGF, basic fibroblast growth factor TAF, tumor angiogenesis factor VEGF, vascular endothelial growth factor.
DOI:
10.1093/carcin/21.3.505
被引量:
年份:
2000
























































通过文献互助平台发起求助,成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用!